\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes
Destination 2 'Environment & health' - HORIZON-HLTH-2024-ENVHLTH-02-two-stage (closed on 19 September 2023)
For the first stage, 90 proposals were submitted under topic HORIZON-HLTH-2024-ENVHLTH-02-06-two-stage.
Destination 4 'Ensuring access to innovative, sustainable and high-quality health care' - HORIZON-HLTH-2024-CARE-04-two-stage (closed on 19 September 2023)
For the first stage, 93 proposals were submitted under topic HORIZON-HLTH-2024-CARE-04-04-two-stage.
For all the above mentioned calls the evaluation results are expected to be communicated on 24 January 2024 at the earliest.
Source: Funding and Tender Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment Horizontal Activities
After lengthy discussions, the final work programme on the horizontal activities has been officially published on the website of the European Commission. First added to Horizon Europe in 2025, this broadly defined work programme supports EU policy goals through four topics: the Clean Industrial Deal, AI in Science, a nature-positive economy... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
